HD-OPM Archive
Topics › Cancer

Vitamin D analog paricalcitol raised tumour response from 9% to 42% in pancreatic cancer

Louis Nervegna · Jun 01, 2026 · ♥ 15 reactions · 0 comments · original Facebook post
CancerSupplements & vitamins
AI summary & key facts

A shared news item on a 36-patient Dana-Farber trial where paricalcitol plus chemotherapy opened the protective barrier around metastatic pancreatic tumours. Small trial, so results are preliminary.

See this earlier post:
↪ Paricalcitol plus chemotherapy raised partial response to 42% vs 9% in pancreatic cancer

#vitamindHD #paracalcitolHD #pancreaticcancerHD #cancerHD #danafarberHD

Research cited

A clinical trial led by the Dana-Farber Cancer Institute, building on Salk Institute research, used a synthetic vitamin D analog called paricalcitol to strip away the protective barrier surrounding metastatic pancreatic tumours, one of the deadliest and most treatment-resistant cancers. In the 36-patient trial, partial tumour destruction responses jumped from just 9 percent with standard chemotherapy to 42 percent when the vitamin D drug was added. The analog reprograms the dense defensive tissue around the tumour to open up, allowing chemotherapy to flood into the cancer cells. Researchers say it offers genuine new hope against a cancer that has resisted progress for decades.
#PancreaticCancer #VitaminD #Oncology #MedicalBreakthrough #ScienceFacts
Disclaimer. Shared for informational purposes only.

No photo description available.
← newer: Aged garlic extract slowed coronary calcium progression in tolder: Experimental pancreatic cancer drug nearly doubled overall s →